Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects
Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insul...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
D. Yu. Belousov [verfasserIn] E. V. Afanasyeva [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Качественная клиническая практика - Izdatelstvo OKI, 2020, (2018), 1, Seite 3-13 |
|---|---|
| Übergeordnetes Werk: |
year:2018 ; number:1 ; pages:3-13 |
| Links: |
|---|
| Katalog-ID: |
DOAJ037139347 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ037139347 | ||
| 003 | DE-627 | ||
| 005 | 20240413174554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2018 xx |||||o 00| ||rus c | ||
| 035 | |a (DE-627)DOAJ037139347 | ||
| 035 | |a (DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a R855-855.5 | |
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a D. Yu. Belousov |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. | ||
| 650 | 4 | |a сахарный диабет | |
| 650 | 4 | |a инсулин гларгин | |
| 650 | 4 | |a инсулин детемир | |
| 650 | 4 | |a фармакоэкономика | |
| 650 | 4 | |a оценка технологий здравоохранения | |
| 653 | 0 | |a Medical technology | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a E. V. Afanasyeva |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Качественная клиническая практика |d Izdatelstvo OKI, 2020 |g (2018), 1, Seite 3-13 |w (DE-627)1760591807 |x 26188473 |7 nnns |
| 773 | 1 | 8 | |g year:2018 |g number:1 |g pages:3-13 |
| 856 | 4 | 0 | |u https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.clinvest.ru/jour/article/view/192 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2588-0519 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2618-8473 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2018 |e 1 |h 3-13 | ||
| author_variant |
d y b dyb e v a eva |
|---|---|
| matchkey_str |
article:26188473:2018----::aaislnnlgeiteibtseltsyecn |
| hierarchy_sort_str |
2018 |
| callnumber-subject-code |
R |
| publishDate |
2018 |
| allfields |
(DE-627)DOAJ037139347 (DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 D. Yu. Belousov verfasserin aut Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. сахарный диабет инсулин гларгин инсулин детемир фармакоэкономика оценка технологий здравоохранения Medical technology Pharmacy and materia medica E. V. Afanasyeva verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2018), 1, Seite 3-13 (DE-627)1760591807 26188473 nnns year:2018 number:1 pages:3-13 https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7 kostenfrei https://www.clinvest.ru/jour/article/view/192 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2018 1 3-13 |
| spelling |
(DE-627)DOAJ037139347 (DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 D. Yu. Belousov verfasserin aut Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. сахарный диабет инсулин гларгин инсулин детемир фармакоэкономика оценка технологий здравоохранения Medical technology Pharmacy and materia medica E. V. Afanasyeva verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2018), 1, Seite 3-13 (DE-627)1760591807 26188473 nnns year:2018 number:1 pages:3-13 https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7 kostenfrei https://www.clinvest.ru/jour/article/view/192 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2018 1 3-13 |
| allfields_unstemmed |
(DE-627)DOAJ037139347 (DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 D. Yu. Belousov verfasserin aut Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. сахарный диабет инсулин гларгин инсулин детемир фармакоэкономика оценка технологий здравоохранения Medical technology Pharmacy and materia medica E. V. Afanasyeva verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2018), 1, Seite 3-13 (DE-627)1760591807 26188473 nnns year:2018 number:1 pages:3-13 https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7 kostenfrei https://www.clinvest.ru/jour/article/view/192 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2018 1 3-13 |
| allfieldsGer |
(DE-627)DOAJ037139347 (DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 D. Yu. Belousov verfasserin aut Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. сахарный диабет инсулин гларгин инсулин детемир фармакоэкономика оценка технологий здравоохранения Medical technology Pharmacy and materia medica E. V. Afanasyeva verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2018), 1, Seite 3-13 (DE-627)1760591807 26188473 nnns year:2018 number:1 pages:3-13 https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7 kostenfrei https://www.clinvest.ru/jour/article/view/192 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2018 1 3-13 |
| allfieldsSound |
(DE-627)DOAJ037139347 (DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 D. Yu. Belousov verfasserin aut Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. сахарный диабет инсулин гларгин инсулин детемир фармакоэкономика оценка технологий здравоохранения Medical technology Pharmacy and materia medica E. V. Afanasyeva verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2018), 1, Seite 3-13 (DE-627)1760591807 26188473 nnns year:2018 number:1 pages:3-13 https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7 kostenfrei https://www.clinvest.ru/jour/article/view/192 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2018 1 3-13 |
| language |
Russian |
| source |
In Качественная клиническая практика (2018), 1, Seite 3-13 year:2018 number:1 pages:3-13 |
| sourceStr |
In Качественная клиническая практика (2018), 1, Seite 3-13 year:2018 number:1 pages:3-13 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
сахарный диабет инсулин гларгин инсулин детемир фармакоэкономика оценка технологий здравоохранения Medical technology Pharmacy and materia medica |
| isfreeaccess_bool |
true |
| container_title |
Качественная клиническая практика |
| authorswithroles_txt_mv |
D. Yu. Belousov @@aut@@ E. V. Afanasyeva @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
1760591807 |
| id |
DOAJ037139347 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ037139347</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174554.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ037139347</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">D. Yu. Belousov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сахарный диабет</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин гларгин</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин детемир</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фармакоэкономика</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">оценка технологий здравоохранения</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Afanasyeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Качественная клиническая практика</subfield><subfield code="d">Izdatelstvo OKI, 2020</subfield><subfield code="g">(2018), 1, Seite 3-13</subfield><subfield code="w">(DE-627)1760591807</subfield><subfield code="x">26188473</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:3-13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.clinvest.ru/jour/article/view/192</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2588-0519</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8473</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">3-13</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
D. Yu. Belousov |
| spellingShingle |
D. Yu. Belousov misc R855-855.5 misc RS1-441 misc сахарный диабет misc инсулин гларгин misc инсулин детемир misc фармакоэкономика misc оценка технологий здравоохранения misc Medical technology misc Pharmacy and materia medica Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects |
| authorStr |
D. Yu. Belousov |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760591807 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
R855-855 |
| illustrated |
Not Illustrated |
| issn |
26188473 |
| topic_title |
R855-855.5 RS1-441 Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects сахарный диабет инсулин гларгин инсулин детемир фармакоэкономика оценка технологий здравоохранения |
| topic |
misc R855-855.5 misc RS1-441 misc сахарный диабет misc инсулин гларгин misc инсулин детемир misc фармакоэкономика misc оценка технологий здравоохранения misc Medical technology misc Pharmacy and materia medica |
| topic_unstemmed |
misc R855-855.5 misc RS1-441 misc сахарный диабет misc инсулин гларгин misc инсулин детемир misc фармакоэкономика misc оценка технологий здравоохранения misc Medical technology misc Pharmacy and materia medica |
| topic_browse |
misc R855-855.5 misc RS1-441 misc сахарный диабет misc инсулин гларгин misc инсулин детемир misc фармакоэкономика misc оценка технологий здравоохранения misc Medical technology misc Pharmacy and materia medica |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Качественная клиническая практика |
| hierarchy_parent_id |
1760591807 |
| hierarchy_top_title |
Качественная клиническая практика |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760591807 |
| title |
Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects |
| ctrlnum |
(DE-627)DOAJ037139347 (DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7 |
| title_full |
Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects |
| author_sort |
D. Yu. Belousov |
| journal |
Качественная клиническая практика |
| journalStr |
Качественная клиническая практика |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
3 |
| author_browse |
D. Yu. Belousov E. V. Afanasyeva |
| class |
R855-855.5 RS1-441 |
| format_se |
Elektronische Aufsätze |
| author-letter |
D. Yu. Belousov |
| author2-role |
verfasserin |
| title_sort |
basal insulin analogues in the diabetes mellitus type 2 control — economic aspects |
| callnumber |
R855-855.5 |
| title_auth |
Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects |
| abstract |
Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. |
| abstractGer |
Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. |
| abstract_unstemmed |
Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects |
| url |
https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7 https://www.clinvest.ru/jour/article/view/192 https://doaj.org/toc/2588-0519 https://doaj.org/toc/2618-8473 |
| remote_bool |
true |
| author2 |
E. V. Afanasyeva |
| author2Str |
E. V. Afanasyeva |
| ppnlink |
1760591807 |
| callnumber-subject |
R - General Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
R855-855.5 |
| up_date |
2024-07-04T00:04:34.516Z |
| _version_ |
1803604694943137792 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ037139347</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174554.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ037139347</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd1e8c84a40d041a5af07d487288bc2c7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">D. Yu. Belousov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Economic aspects of insulin analogues — glargine and detemir — in the control of diabetes mellitus type 2 (DM 2) has been prepared in according to needs of the Russian health care system. It has been done that for equal control of DM 2 insulin glargine should be administered in less doses than insulin glargine based on randomized clinical trials results. Results of Russian observational studies of real practice do not show diff erence in doses of both. In the same time glargine has a better effi cacy and safety than detemir based on amount of patients with DM 2 reached targeted levels of control and hypoglycemic events. Clinicaleconomic analysis as well as sensitive analysis did not fi nd any economic advantages of detemir compare with glargine having higher cost for pack. Needed doses diff erentiation of glargine and detemir for equal results of DM 2 control should be taken into account for reimbursement.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сахарный диабет</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин гларгин</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин детемир</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фармакоэкономика</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">оценка технологий здравоохранения</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Afanasyeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Качественная клиническая практика</subfield><subfield code="d">Izdatelstvo OKI, 2020</subfield><subfield code="g">(2018), 1, Seite 3-13</subfield><subfield code="w">(DE-627)1760591807</subfield><subfield code="x">26188473</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:3-13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d1e8c84a40d041a5af07d487288bc2c7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.clinvest.ru/jour/article/view/192</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2588-0519</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8473</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">3-13</subfield></datafield></record></collection>
|
| score |
7.401636 |